New clinical trial studies the addition of immunotherapy to chemotherapy for patients with biliary tract carcinoma

A new clinical trial is studying the addition of immunotherapy to a chemotherapy regimen to test if it can improve survival for patients with biliary tract carcinoma (BTC), a rare but aggressive form of cancer. BTC originates in the bile ducts, the slender tubes that carry bile, a digestive fluid, from the liver into the small intestine. Capecitabine and oxaliplatin, known together as CAPOX, are chemotherapy drugs that stop cancer cells from dividing and proliferating. Pembrolizumab, an immunotherapy drug, blocks a protective mechanism on cancer cells and allows the patient’s own immune system to destroy those cancer cells. Tim Greten, M.D., of the Thoracic and Gastrointestinal Oncology Branch is leading this study to see if this combination can improve survival for BTC patients for whom surgery is not an option. For more information about this trial, visit: To search all CCR clinical trials, please visit:

Summary Posted: Thu, 06/01/2017